Note 9 - Liability Related to Sale of Future Royalties (Details Textual) - USD ($) $ in Thousands |
9 Months Ended | 78 Months Ended | |||
|---|---|---|---|---|---|
May 31, 2022 |
Sep. 18, 2015 |
Sep. 30, 2022 |
Sep. 30, 2021 |
Mar. 31, 2022 |
|
| Proceeds From Sale of Royalty and Milestone Rights | $ 65,000 | ||||
| Consideration Paid for Termination of Royalty Monetization | $ 100 | $ 100 | $ 100 | ||
| Gain on Termination of Liability Related to Sale of Future Royalties | $ 84,100 | $ 84,152 | $ (0) | ||
| Effective Annual Interest Rate | 3.20% | 3.60% | |||
| SWK [Member] | |||||
| Percentage of Royalties and Rights Under Agreement | 75.00% | ||||
| SWK [Member] | First Four Commercial Milestones [Member] | |||||
| Percentage of Royalties and Rights Under Agreement | 80.00% | ||||
| Commercial Milestones Value Maximum Amount Available | $ 35,600 | ||||
| AcelRX [Member] | First Four Commercial Milestones [Member] | |||||
| Commercial Milestones Value Maximum Amount Available | $ 44,500 | ||||